Vector of Coronavirus 2019-nCoV and Virus background with disease cells.

The COVID-19 global pandemic is affecting people around the world and is of great concern to many cancer patients. In addition to information about the virus and how to protect ourselves, kidney cancer patients need information about cancer treatment, follow-up care and other cancer-specific details about managing our health during the pandemic.

While the local situation and individual risk of each cancer patient differs, there is a universal need for credible and reliable information. On this page, IKCC has curated information from trusted, evidence-based sources about COVID-19, as well as cancer-specific resources.

If your organisation has information to be included, please contact Julia Black at info@ikcc.org.

COVID-19 vaccines and kidney cancer patients

Vaccination against COVID using approved COVID-19 vaccines has been shown to be effective and safe. There is a small risk of developing an allergic reaction to the vaccine, and discussion of these risks needs to occur with your doctor prior to receiving the vaccine.

There is no clear evidence that the vaccine will be less effective, or side effects to the vaccine will be worsened by receiving either targeted drugs or immune therapy typically administered to patients with kidney cancer, nor is having kidney cancer a reason to avoid the vaccine.

The IKCC Medical Advisory Board believes that the benefits of being vaccinated against COVID strongly outweigh the risks of the vaccines themselves. Ultimately, this is a decision you need to make in conjunction with your doctor.

Guidance on the COVID-19 vaccine for patients with cancer participating in oncology clinical trials can be found here: https://www.nature.com/articles/s41571-021-00487-z


International Organisations and Societies:

 

The Impact of COVID-19 on Cancer Patient Organisations

COVID-19: Impact on Cancer Patient Organisations Worldwide in 2020 (Part 2)

GCCN’s first Coalition Connection event examined the effects of COVID-19 and the innovative strategies patient advocacy organisations have employed in the wake of this global health crisis. Watch the recording here.

Global Alliance Joint Statement on COVID-19
ASCO: American Society of Clinical Oncology
ESMO: European Society of Medical Oncology Cancer Care during the COVID-19 Pandemic: An ESMO Guide of Patients

ESMO Webinar Series: SARS-CoV-2 Vaccination: Special Considerations in Patients with Cancer
UICC: Union for International Cancer Control

WHO: World Health Organization

Information and guidance by country:

 

AustraliaAustralian Government Department of HealthAustralian Government Department of Health
BrazilMinistry of Health

Pan American Health Organisation
Ministry of Health

Pan American Health Organisation

COVID e Cancer de Rim
Infomed Consent And Algorithm COVID 19
CanadaGovernment of Canada
FranceGovernment of FranceGovernment of France
GermanyFederal Ministry of Health

Cancer Information Service
Federal Ministry of Health

Cancer Information Service
IndiaIndian Council of Medical ResearchIndian Council of Medical Research
JapanJapanese Cancer SocietyJapanese Cancer Society
NetherlandsNational Institute of Public Health

Government
National Institute of Public Health

Government
SpainSpanish Society of Cancer

Spanish Group of Genitourinary tumors
Spanish Society of Cancer

Spanish Group of Genitourinary tumors
SwedenGovernment Offices of Sweden

Government Health
Government Offices of Sweden

Government Health
UKGovernment of the UK

National Health Service (NHS)

National Institute for Health and Care Excellence  ( N I C E )

Cancer Research UK
Government of the UK

National Health Service (NHS)

National Institute for Health and Care Excellence ( N I C E )

Cancer Research UK
USANIH National Cancer Institute

US Food & Drug Administration FDA

American Cancer Society
NIH National Cancer Institute

US Food & Drug Administration FDA

American Cancer Society

Videos/Podcasts

 

A Podcast by The Uromigos
Discussing COVID-19 and Renal Cell Carcinoma
Episode 10

 

 

 

VHL in the COVID Era:
Management Approaches and Modifications